Registrace
- Zlevněná registrace do 8. prosince 2009
- Běžná registrace do 18. února 2010
- Online registrace
- Oznámení (PDF)
13:00 Welcome and introduction
Session I: Myeloma
Moderator: Jesus San Miguel, MD and Bertrand Coiffier, MD
13:05
Overview of newly diagnosed patients
Speaker invited
13:20
DEBATE: First-line treatment in the transplant eligible patient
Jean-Luc Harousseau, MD
Antonio Palumbo, MD
13:50
Current and emerging options for relapsed myeloma
Jesus San Miguel, MD
14:10
DEBATE: Best salvage therapy for the relapsed patient
Meletios A. Dimopoulos, MD
Jesus San Miguel, MD
14:40
The role of VTE prophylaxis in myeloma
Antonio Palumbo, MD
15:00
Summary of the IMW consensus on response criteria and relevant outcomes
Joan Bladé, MD
15:15
Chair take-home points for the clinician
15:20
Break
Session II: Chronic Lymphocytic Leukemia
Moderator: Eva Kimby, MD, PhD
15:40
Role of the microenvironment in CLL
Speaker invited
16:00
Monoclonal B-cell lymphocytosis and CLL
Paulo Ghia, MD
16:20
Case discussion: Optimal management of the low risk patient
Speaker invited
16:50
Case discussion: Optimal therapy for the high risk patient
Speaker invited
17:20
DEBATE: Management of the double-refractory patient
Speakers invited
17:50
Panel discussion
18:00
Chair take-home points for the clinician and adjourn
Saturday, 27 February 2010
Session III: Follicular Lymphoma
Moderator: Gilles Salles, MD and Eva Kimby, MD, PhD
9:00
Role of the microenvironment in CLL
Speaker invited
9:20
Overview of maintenance therapy
Gilles Salles, MD
9:40
DEBATE: Is follicular lymphoma curable?
Michele Ghielmini, MD (no)
Christian Buske, MD (yes)
10:10
DEBATE: The role of stem cell transplant in patients with relapsed follicular lymphoma
Bertrand Coiffier, MD (for)
Rien van Oers, MD (against)
10:40
Panel discussion and chair take-home points for the clinician
10:50 Break
Saturday, 27 February 2010 (...cont'd)
Session IV: Mantle Cell Lymphoma
Moderator: Eva Kimby, MD, PhD
11:10
Biology of mantle cell lymphoma
Andrew Rosenward, MD
11:30
Case discussion: Mantle cell lymphoma therapy in young and old patients
Speaker invited
11:50
Maintenance therapy after first-line and second-line therapy in MCL
Michele Ghielmini, MD
12:10
DEBATE: Autologous versus allogeneic transplantation in mantle cell lymphoma
Speaker invited (auto)
Norbert Schmitz, MD (allo)
12:40
Panel discussion and chair take-home points for the clinician
13:00
Lunch
Session V: Aggressive B-cell Non-Hodgkin Lymphoma
Moderator: Bertrand Coiffier, MD and Michael Pfreundschuh, MD
14:30
Biology and treatment of bulky and mediastinal large B-cell lymphoma
Speaker invited
14:50
DEBATE: Prevention and treatment of central nervous system disease
Michael Pfreundschuh, MD
Speaker invited
15:20
DEBATE: Improving high-risk DLBCL in both the young and the elderly
Bertrand Coiffier, MD
Michael Pfreundschuh, MD
15:50
PROPOSITION: Same treatment for germinal centre (GC) and non-GC patients?
Speaker invited (no)
Speaker invited (yes)
16:10
Panel discussion and chair take-home points for the clinician
16:20
Break
Session VI: T-Cell Lymphoma
Moderator: Bertrand Coiffier, MD
16:40
Pathology overview of T-cell lymphoma
Andrew Rosenward, MD
17:00
Case discussion: Treatment of nasal type lymphoma (localized and disseminated)
Speaker invited
17:20
DEBATE: Transplantation in young patients
Speaker invited (for)
Nicolas Mounier, MD (against)
17:50
Panel discussion and chair take-home points for the clinician
18:00
Adjourn
Sunday, 28 February 2010
Session VII: Hodgkin’s Disease
Moderator: Andreas Engert, MD
9:00
Overview: Improving efficacy and reducing toxicity of localized HD
Andreas Engert, MD
9:20
Radiation in Hodgkin’s disease
Lena Specht, MD, PhD
9:40
Treatment of relapsing patients
Christophe Fermé, MD
10:00
Allogeneic transplantation
Norbert Schmitz, MD
10:20
Panel discussion and chair take-home points for the clinician
10:30
Break
Session VIII: SPECIAL SESSION –Acute Lymphoblastic Leukemia
Moderator: Dieter Hoelzer, MD
11:00
Recent diagnostic approaches and molecular genetics in acute lymphoblastic leukemia (ALL)
Speaker invited
11:25
New treatment options in adult ALL including targeted therapy
Dieter Hoelzer, MD
11:50
Update on achievements in childhood ALL
Speaker invited
12:15
Minimal residual disease: The most prognostic parameters to stratify and treat ALL
Nicola Gökbuget, MD
12:40
Panel discussion and chair take-home points for the clinician
13:00
Adjourn
Kontakt: meetings@imedex.com
Web: http://www.imedex....ements/a138-01.asp
- Přidat do kalendáře: 2010-02-26 00:00:00 2010-02-28 23:59:59 Europe/Prague 6th European Congress on Hematologic Malignancies from Clinical Science to Clinical Practice InterContinental Carlton Cannes, Cannes, France